Long term safety of GnRH agonist therapy in precocious puberty: An evaluation of reproductive function, bone density and body composition

Peter A. Lee, Lawrence A. Silverman

Research output: Contribution to journalReview article

Abstract

While the use of GnRH agonists is viewed as a very safe therapy for central precocious puberty, outcome safety issues after therapy concerning completion of puberty, reproductive function, bone mineral density and body composition need to be further documented. This review article raises no significant concerning abnormailities of the recovery of the pubertal reproductive axis, evidence of normal fertility, bone density or body composition Hence, to date, such therapy continues to have a clearly positive risk:benefit ratio.

Original languageEnglish (US)
Pages (from-to)300-305
Number of pages6
JournalPediatric Endocrinology Reviews
Volume4
Issue numberSUPPL. 3
StatePublished - Jun 1 2007

Fingerprint

Precocious Puberty
Body Composition
Gonadotropin-Releasing Hormone
Bone Density
Safety
Puberty
Fertility
Therapeutics
Odds Ratio

All Science Journal Classification (ASJC) codes

  • Pediatrics, Perinatology, and Child Health
  • Endocrinology, Diabetes and Metabolism

Cite this

@article{1d1e48ed9478481c807665df32a0f693,
title = "Long term safety of GnRH agonist therapy in precocious puberty: An evaluation of reproductive function, bone density and body composition",
abstract = "While the use of GnRH agonists is viewed as a very safe therapy for central precocious puberty, outcome safety issues after therapy concerning completion of puberty, reproductive function, bone mineral density and body composition need to be further documented. This review article raises no significant concerning abnormailities of the recovery of the pubertal reproductive axis, evidence of normal fertility, bone density or body composition Hence, to date, such therapy continues to have a clearly positive risk:benefit ratio.",
author = "Lee, {Peter A.} and Silverman, {Lawrence A.}",
year = "2007",
month = "6",
day = "1",
language = "English (US)",
volume = "4",
pages = "300--305",
journal = "Pediatric Endocrinology Reviews",
issn = "1565-4753",
publisher = "YS Medical Media Ltd.",
number = "SUPPL. 3",

}

TY - JOUR

T1 - Long term safety of GnRH agonist therapy in precocious puberty

T2 - An evaluation of reproductive function, bone density and body composition

AU - Lee, Peter A.

AU - Silverman, Lawrence A.

PY - 2007/6/1

Y1 - 2007/6/1

N2 - While the use of GnRH agonists is viewed as a very safe therapy for central precocious puberty, outcome safety issues after therapy concerning completion of puberty, reproductive function, bone mineral density and body composition need to be further documented. This review article raises no significant concerning abnormailities of the recovery of the pubertal reproductive axis, evidence of normal fertility, bone density or body composition Hence, to date, such therapy continues to have a clearly positive risk:benefit ratio.

AB - While the use of GnRH agonists is viewed as a very safe therapy for central precocious puberty, outcome safety issues after therapy concerning completion of puberty, reproductive function, bone mineral density and body composition need to be further documented. This review article raises no significant concerning abnormailities of the recovery of the pubertal reproductive axis, evidence of normal fertility, bone density or body composition Hence, to date, such therapy continues to have a clearly positive risk:benefit ratio.

UR - http://www.scopus.com/inward/record.url?scp=34250214192&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34250214192&partnerID=8YFLogxK

M3 - Review article

AN - SCOPUS:34250214192

VL - 4

SP - 300

EP - 305

JO - Pediatric Endocrinology Reviews

JF - Pediatric Endocrinology Reviews

SN - 1565-4753

IS - SUPPL. 3

ER -